Christopher N. Fortner

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Aquaporin 5-deficient mouse lungs are hyperresponsive to cholinergic stimulation

Carissa M. Krane, Christopher N. Fortner, Arthur R. Hand et al. · Proceedings of the National Academy of Sciences · 2001 · 113 citations · Full text

Life Sciences, Pharmacology, Hypersensitivity +15

Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy

Christopher N. Fortner, Julie M. Seguin, Denise M. Kay · Journal of Cystic Fibrosis · 2021 · 110 citations

Medicine, Child Health, Pediatrics +14

ROCK1 Phosphorylates and Activates Zipper-interacting Protein Kinase

Laura Hagerty, Douglas H. Weitzel, Jenica Chambers et al. · Journal of Biological Chemistry · 2006 · 88 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor

Bethany Collins, Christopher N. Fortner, Amanda Cotey et al. · Journal of Cystic Fibrosis · 2021 · 77 citations · Full text

Pharmacy, Pediatrics, Pharmacology +12